2 Cardiovascular Biotech Companies You Should Know About

cardiovascular biotech companies

We all know that heart disease is the leading cause of death in the United States. What you might not know is that there are a number of innovative Cardiovascular Biotech Companies working on developing new treatments and cures for cardiovascular disease. Here are two of them.

Take a look at these companies

CVRx Inc

CVRx is a biotech company based in Minneapolis, Minnesota that is focused on the development of implantable devices for the treatment of hypertension and heart failure. The company’s flagship product is the Barostim neo, an implantable device that is designed to stimulate the sympathetic nervous system in order to lower blood pressure. CVRx has raised over $200 million in funding from investors such as GE Ventures, Oak HC/FT, and Polaris Partners.

The business has created its own implanted device to treat excessive blood pressure and heart failure. BarostimTM stimulates carotid baroreceptors, the body’s natural blood flow regulating mechanism, which sends signals to the brain to regulate cardiovascular function.

Patient Stories on CVRx: The patient experiences and quotations are authentic and recorded. These tales represent a single individual’s experience and do not constitute an indication, recommendation, warranty, or guarantee of how other individuals will react to CVRx technology.

MyoKardia Inc.

MyoKardia Inc., a biomedical firm launched in 2013, creates small molecule therapies that address critical clinical requirements for individuals suffering from hereditary cardiac disease. MyoKardia targets hypertrophic cardiomyopathy and dilated cardiomyopathy, which affect about 1 million people in the United States. Hypertrophic cardiomyopathy causes heart wall thickening and is the greatest cause of abrupt cardiac mortality in young athletes. Dilated cardiomyopathy causes the heart walls to weaken and the heart chambers to expand. Cardiomyopathy can occur at any age, and more than 30,000 children in the United States, ranging in age from newborns to 18-year-olds, have some kind of cardiomyopathy – a patient population equivalent to that of cystic fibrosis.

Leslie Leinwand, a professor at the University of Colorado in Boulder and the chief scientific officer of the BioFrontiers Institute, is one of the four MyoKardia founders and an internationally recognized expert in the genetics of the heart and muscles. In addition to Leinwand, the company’s co-founders include Dr. Christine Seidman, director of the Cardiovascular Genetics Center at Brigham and Women’s Hospital in Boston, Professor Jonathan Seidman, and Professor James Spudich, both of the Departments of Genetics at Harvard Medical School and Stanford University. Leinwand and Spudich have worked with the myosin protein, which is present in cells and is responsible for muscle contraction, for a combined seven decades. Couple Jonathan and Christine Seidman are well known for figuring out the genetics of hypertrophic cardiomyopathy.

Much more to discover about Cardiovascular Biotech Companies

These are just three of the many innovative companies working on developing new treatments for cardiovascular disease. With so much promising research being done, there is reason to be hopeful that we will soon see major advancements in the fight against this devastating disease.